Medpace (MEDP) is selling off sharply after its Q1 2026 report highlighted a key red flag for a contract research organization: bookings momentum. The company posted net new business awards of $618.4 million for the quarter and a net book-to-bill ratio of 0.88x, meaning new awards did not keep pace with revenue recognized—raising concerns that revenue growth could slow if bookings don’t rebound. (pharmiweb.com)

On headline earnings, Medpace delivered a solid quarter: revenue of $706.6 million (+26.5% year over year) and GAAP EPS of $4.28, both ahead of consensus estimates. The market reaction suggests investors are looking past the near-term beat and focusing on forward indicators like award flow and book-to-bill, which often drive CRO valuation more than a single-quarter EPS surprise. (markets.financialcontent.com)

For CROs, the book-to-bill ratio is a fast read on pipeline health because it compares net new business awards to current revenue. A figure below 1.0x implies the company is consuming backlog faster than it is replenishing it, which can pressure future growth and investor confidence—especially for premium-multiple names. Medpace’s Q1 2026 book-to-bill of 0.88x is reinforcing a market narrative that bookings visibility is the swing factor for 2026 performance. (pharmiweb.com)

Investors will focus on whether bookings stabilize in coming quarters and whether backlog supports the existing 2026 outlook. Near-term attention is likely to center on management commentary around conversion, cancellations, sponsor behavior, and whether the company can drive book-to-bill back above 1.0x as the year progresses. (quiverquant.com)